Samsung Bioepis Co. Ltd. Deal History & Licensing Activity
Samsung Bioepis Co. Ltd. is a large biotech. The company currently has 2 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
2
Top Modality
N/A
Focus Area
Solid Tumors
Samsung Bioepis Co. Ltd. Pipeline Focus
Therapeutic areas and modalities where Samsung Bioepis Co. Ltd. is most active based on deal history and clinical trial data.
Therapeutic Areas
Samsung Bioepis Co. Ltd. Clinical Pipeline
Samsung Bioepis Co. Ltd. has 2 active clinical trials across 2 development phases.
1
Phase 1
1
Phase 3
See How Your Asset Matches Samsung Bioepis Co. Ltd.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
About Samsung Bioepis Co. Ltd. Licensing & Deal Activity
Samsung Bioepis Co. Ltd. is a large biotech company that has been actively engaged in licensing transactions across the biopharma landscape.
Key therapeutic areas of focus for Samsung Bioepis Co. Ltd. include Solid Tumors (2 deals and trials).
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Samsung Bioepis Co. Ltd. and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Samsung Bioepis Co. Ltd.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.